On May 23, 2025, PolyPeptide announced that it has secured additional financing of EUR 40 m under its revolving credit facility (RCF) increasing the available capital commitments to a total of EUR 151 m, with UBS as coordinator and agent, and together with Danske Bank and Zürcher Kantonalbank each as mandated lead arranger and lender.

PolyPeptide is a global Contract Development & Manufacturing Organization (CDMO) specializing in the development and manufacturing of peptide- and oligonucleotide-based active pharmaceutical ingredients for the biotech and pharmaceutical industries.

Homburger advised UBS and the other banks with regard to all Swiss legal aspects of the financing transaction. The Homburger team was led by Jürg Frick and included Nathalie Scherrer (both Financing and Investment Products) and Stefan Oesterhelt (Tax).

 

Contact
Johanna Schmid / Marketing / [email protected]

More from Homburger